| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 07/20/2023 | 100% | B of A Securities | → $14 | Reinstates | → Buy |
| 07/17/2023 | 85.71% | Cantor Fitzgerald | → $13 | Reiterates | Overweight → Overweight |
| 07/17/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | Buy → Buy |
| 05/18/2023 | 85.71% | Cantor Fitzgerald | → $13 | Initiates Coverage On | → Overweight |
| 03/28/2023 | 85.71% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 03/28/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 02/02/2023 | 114.29% | HC Wainwright & Co. | → $15 | Reiterates | → Buy |
| 11/15/2022 | 128.57% | Credit Suisse | $17 → $16 | Maintains | Outperform |
| 10/05/2022 | 214.29% | BTIG | $15 → $22 | Maintains | Buy |
| 07/15/2022 | 114.29% | BTIG | → $15 | Initiates Coverage On | → Buy |
| 06/30/2022 | 114.29% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 03/29/2022 | 142.86% | Credit Suisse | $26 → $17 | Maintains | Outperform |
| 01/21/2022 | 100% | B of A Securities | $16 → $14 | Upgrades | Neutral → Buy |
| 07/26/2021 | 285.71% | UBS | → $27 | Initiates Coverage On | → Buy |
| 07/26/2021 | 185.71% | B of A Securities | → $20 | Initiates Coverage On | → Neutral |
| 07/26/2021 | 271.43% | Credit Suisse | → $26 | Initiates Coverage On | → Outperform |
| 07/26/2021 | 285.71% | Stifel | → $27 | Initiates Coverage On | → Buy |
What is the target price for Acumen Pharmaceuticals (ABOS)?
The latest price target for Acumen Pharmaceuticals (NASDAQ: ABOS) was reported by HC Wainwright & Co. on August 9, 2023. The analyst firm set a price target for $15.00 expecting ABOS to rise to within 12 months (a possible 114.29% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acumen Pharmaceuticals (ABOS)?
The latest analyst rating for Acumen Pharmaceuticals (NASDAQ: ABOS) was provided by HC Wainwright & Co., and Acumen Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Acumen Pharmaceuticals (ABOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acumen Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acumen Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
Is the Analyst Rating Acumen Pharmaceuticals (ABOS) correct?
While ratings are subjective and will change, the latest Acumen Pharmaceuticals (ABOS) rating was a reiterated with a price target of $0.00 to $15.00. The current price Acumen Pharmaceuticals (ABOS) is trading at is $7.00, which is within the analyst's predicted range.